Search
Powered By HealthLine
Health Tools
 Neurology Health Center
 Understanding Multiple Sclerosis
 Fibromyalgia Basics
 Video: Alzheimer's Disease
 Migraine - What is it?
Featured Conditions
 Alzheimer's
 Chronic Pain
 Multiple Sclerosis
 Depression
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

New Botox for Foreheads

Ivanhoe Broadcast News


Related Encyclopedia
 border=
Acoustic Neurinoma
Amenorrhea
Amniocentesis
Amniocentesis and CVS
More...

Related Healthscout Videos
 border=
Say Ahh! The First Oral Treatment for MS
Coming Around: Coma Breakthroughs
Baby Steps: Fertility Findings
Saving Memories with a Shake: The Alzheimer's Drink
More...

Related Animations
 border=
Breast Reduction
Breast Self-Exam Video
Erectile Dysfunction
Facelift
More...

Related Drug Information
 border=
Actonel
Adderal XR
Concerta
Coumadin
More...

Related News Articles
 border=
Prenatal Antipsychotic Drugs Linked to Motor Delays: Study
Coffee Drinking in Pregnancy Won't Lead to Sleepless Baby: Study
1 in 5 Pharmacies Hinders Teens' Access to 'Morning-After' Pill: Study
'Freezing' Secondary Breast Cancer Tumors Shows Promise
More...

(Ivanhoe Newswire) A new kind of Botox could be the answer for forehead wrinkles.

Used abroad for more than 15 years to treat neurological disorders and wrinkles, Reloxin a new Clostridium botulinum toxin type A has been shown to be well tolerated and improve the appearance of severe forehead lines in recent America studies.

Text Continues Below



Small doses of Reloxin were injected into 1,200 patients at five injection sites in the forehead. Up to five consecutive treatments were administered over the next 13-months, with a minimum of 85 days between injections.

Most patients (93 to 95 percent) reported a response to treatment within one week of treatment and maintained the clinical effect over the duration of the study with multiple treatments. Adverse effects were experienced by 808 patients, including injection site reactions and nervous system disorders, like headache and eye drooping.

Notably, Medicis Pharmaceutical Corporation, who manufacturers Reloxin, provided funding for this study, and the co-author of the study owns stock in and consults for Medicis.

SOURCE: Archives of Facial Plastic Surgery, 2009;11:77-83

Sign up for a free weekly e-mail on Medical Breakthroughs called First to Know by clicking here.

 

If this story or any other Ivanhoe story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Melissa Medalie at mmedalie@ivanhoe.com.

 

 

This article was reported by Ivanhoe.com, who offers Medical Alerts by e-mail every day of the week. To subscribe, go to: http://www.ivanhoe.com/newsalert/.




Last updated 3/17/2009

Related Links
 border=
From Healthscout's partner site on chronic pain, ChronicPainConnection.com
Find ways to get chronic pain relief!
Find a right treatment for your chronic pain
Join our community - your chronic pain support group.





HealthScout is a part of HealthCentral
About Us   Our Blog   Contact Us   Privacy Policy   Terms of Use   Site Map  
Copyright © 2001-2013. The HealthCentralNetwork, Inc. All rights reserved.
Advertising Policy   Editorial Policy Advertise With Us   Anti-Spam Policy   PR Newswire